News
At the recent SEC meeting for endocrinology and metabolism, the expert panel reviewed the proposal along with the ...
10d
TipRanks on MSNAstraZeneca’s Latest Study on Balcinrenone/Dapagliflozin: Key Insights for Investors
The study tested the effects of balcinrenone/dapagliflozin, a combination drug, in different conditions: fasted, fed, and with the P-gp inhibitor quinidine. The goal was to understand how these ...
8d
TipRanks on MSNAstraZeneca’s Phase I Study on Balcinrenone/Dapagliflozin: Key Insights for Investors
The study tested the effects of balcinrenone/dapagliflozin, a drug combination, both in fed and fasted states, and with the addition of quinidine, a P-gp inhibitor. The purpose is to understand how ...
The UK’s NHS Business Services Authority's annual 'Prescribing for Diabetes - England 2015/16 to 2024/25' report reveals that diabetes treatments now account for 15% of all NHS prescription spending, ...
The decision comes after evidence suggested these drugs protect the heart and kidneys as well as controlling blood sugar, ...
AstraZeneca PLC thrives with $54B revenue and 14 blockbusters in 2024, fueled by oncology and rare disease growth. Click for ...
Today’s announcement (August 20) on draft guidelines from the UK’s National Institute for Health and Care Excellence (NICE) ...
GPs could face a rise in prescribing and monitoring work under draft NICE guidelines recommending earlier use of newer type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results